ReviewCureus2026
Dried Powder Formulation of Ksheerapaka for the Management of Primary Dysmenorrhea: A Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysmenorrhea is a prevalent and recurrent gynaecological disorder characterised by menstrual pain arising from inflammatory, neuroendocrine, and functional mechanisms, often inadequately managed by long-term conventional therapies. Ayurveda conceptualises this condition as Udavartini Yonivyapad, attributed to vitiation and disordered movement of Apana Vata, providing a functional framework for holistic management. This review aims to critically examine primary dysmenorrhea from both biomedical and Ayurvedic perspectives and to evaluate the therapeutic relevance of Ksheerapaka, with particular emphasis on the rationale for developing a dried powder formulation to enhance clinical applicability. A narrative review was conducted using peer-reviewed literature retrieved from PubMed and Scopus, published between 2015 and 2025, focusing on dysmenorrhea, Ksheerapaka, milk-based Ayurvedic formulations, and pharmaceutical dosage form innovations. Evidence from clinical, experimental, and observational studies indicates that Ksheerapaka exhibits analgesic, anti-inflammatory, Vata-pacifying, and tissue-nourishing properties, with consistent benefits reported in gynaecological and pain-related conditions; however, dysmenorrhea-specific clinical evidence remains limited. The review identifies key pharmaceutical challenges associated with the classical liquid formulation, including limited stability, dosing variability, and reduced patient adherence. Reformulation into a dried powder form is highlighted as a scientifically sound strategy to improve shelf life, standardisation, dosing precision, and usability, while preserving therapeutic intent. The review concludes that dried powder Ksheerapaka represents a promising integrative approach for primary dysmenorrhea management, but systematic formulation development and targeted clinical evaluation are needed to support evidence-based adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.